A5101912563- Genetic Neurodegenerative Diseases
- Mitochondrial Function and Pathology
- Drug Transport and Resistance Mechanisms
- Metal complexes synthesis and properties
- Chronic Lymphocytic Leukemia Research
- RNA Research and Splicing
- Muscle Physiology and Disorders
- Chronic Myeloid Leukemia Treatments
- Inflammatory mediators and NSAID effects
- Cancer, Hypoxia, and Metabolism
- Amyotrophic Lateral Sclerosis Research
- Nanoparticle-Based Drug Delivery
- DNA and Nucleic Acid Chemistry
- Eosinophilic Disorders and Syndromes
- Lung Cancer Research Studies
- RNA Interference and Gene Delivery
- Cancer therapeutics and mechanisms
Chinese University of Hong Kong
2015-2025
Abstract MicroRNAs (miRNAs) are small non-coding RNAs that play crucial roles in post-transcriptional gene regulation. Poly(A) RNA polymerase D5 (PAPD5) catalyzes the addition of adenosine to 3′ end miRNAs. In this study, we demonstrate Yin Yang 1 protein, a transcriptional repressor PAPD5, is recruited both foci and protein aggregates, resulting an upregulation PAPD5 expression Huntington’s disease (HD). Additionally, identify subset PAPD5-regulated miRNAs with increased adenylation reduced...
Pelitinib is a potent irreversible EGFR TK inhibitor currently in clinical trials for the treatment of lung cancer. Hyperthermia has been applied concomitantly with chemotherapy and radiotherapy to enhance outcome. In this study, we investigated ability combination pelitinib other conventional anticancer drugs specifically target cancer cells up-regulated efflux transporters ABCB1/ABCG2 after hyperthermia as novel way eradicate stem-like responsible recurrence.Alterations intracellular...
Imatinib, a multitargeted tyrosine kinase inhibitor, exhibits potent anticancer activity against leukemia harboring the Bcr-Abl oncogene and some solid tumors overexpressing c-kit PDGFR. However, its clinical efficacy is severely compromised by emergence of resistance primarily due to acquired mutations in domain. In this study, we showed that combination imatinib with platinum (Pt)-based agents, including cisplatin oxaliplatin, exhibited synergistic cytotoxic effect specifically Bcr-Abl+...
Abstract Polyglutamine (PolyQ) diseases are progressive neurodegenerative disorders caused by both protein- and RNA-mediated toxicities. We previously showed that a peptidyl inhibitor, P3, which binds directly to expanded CAG RNA can inhibit RNA-induced nucleolar stress suppress neurotoxicity. Here we report N-acetylated C-amidated derivative of P3V8, more than 20-fold increase in its affinity for RNA. The P3V8 peptide also potently alleviated cytotoxicity vitro , suppressed polyQ...
Abstract Three molecular targeted tyrosine kinase inhibitors (TKI) were conjugated to classical platinum-based drugs with an aim circumvent TKI resistance, predominately mediated by the emergence of secondary mutations on oncogenic kinases. The hybrids found maintain specificity towards same kinases as original TKI. Importantly, they are remarkably less affected presumably due their unique structure and observed dual mechanism anticancer activity (kinase inhibition DNA damage). study is also...
We have recently reported that vatalanib, an orally active small molecule multi-tyrosine kinase inhibitor (Hess-Stumpp et al., 2005 [1]), can sensitize multidrug resistant (MDR) colon cancer cells to chemotherapy under hypoxia by inhibiting two MDR transporters ABCB1 and ABCG2 (To 2015 [2]). This data article describes the possible circumvention of resistance specifically platinum (Pt)-based anticancer drugs vatalanib via inhibition other efflux ABCC2 ATP7A. Data from flow cytometric...
<title>Abstract</title> MicroRNAs (miRNAs) are small non-coding RNAs responsible for RNA silencing and the posttranscriptional regulation of gene expression. Poly(A) polymerase D5 (PAPD5) catalyzes addition adenosine to 3′ end miRNAs, which promotes their subsequent degradation. In this study, we demonstrated that Yin Yang 1 (YY1) protein, a transcriptional repressor PAPD5, was recruited both foci protein aggregates, caused upregulation PAPD5 expression in Huntington’s disease (HD). We...
Abstract Cancer microenvironment is characterized by significantly lower oxygen concentration. This hypoxic condition known to reduce drug responsiveness cancer chemotherapy via multiple mechanisms, among which the upregulation of an efflux transporter ABCG2 confers resistance a wide variety structurally unrelated anticancer drugs. Vatalanib (PTK787) multitargeted tyrosine kinase inhibitor for VEGFR2, Flt and c-Kit, exhibit potent activity in vitro vivo. We investigated potentiation effect...